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Introduction
Type 2 diabetes mellitus (DM) and heart failure (HF) are common chronic disorders that
affect 29 million and 6.5 million Americans respectively1. While both often occur individually,
there is an increase rate of the two diseases occurring concomitantly. It is estimated that 1926% of patients with DM having clinically significant HF2 and 10-47% of patients with HF
having evidence of DM1, both independent of other risk factors. This association between
DM and HF is well documented, but the evidence supporting diabetic cardiomyopathy is less
understood. This is due to the presence of other comorbid conditions such as hypertension
(HTN) and coronary artery disease (CAD), both of which are independently associated with
the development of HF3.

The development of DCM is related to the effects of DM systemically, on the myocardium,
and directly on cardiomyocytes3. Hyperglycemia, hyperinsulinemia, and insulin resistance
are the major contributors to the pathogenesis of DCM, causing autonomic dysfunction,
oxidative stress, and altered cellular metabolism (Figure F). This results in cardiac
hypertrophy and fibrosis, dysregulation of the renin-angiotensin-aldosterone system
(RAAS), and the formation of advanced glycation end
products (AGEs), all of which contribute to the eventual
development of HF1,3. Additionally, DM is also a major
risk factor for CAD by increasing the arthogenicity of
lipids and accelerating the formation atherosclerosis;
therefore also contributing indirectly to the development
of HF1.

Currently, Diabetic Cardiomyopathy (DCM) is defined as a clinical condition of ventricular
dysfunction that occurs in the absence of significant CAD, HTN, or valvular disorders in a
patient with DM1,2. This idea of a primary DM induced HF is important because it impacts the
treatment of DM both independent and in the absence of CAD, HTN, or valvular disorders.

Case Report
History: A 34-year-old African American female with a past medical history of type 2
diabetes was admitted to our hospital from an outside emergency department due to
anemia. History was obtained from the patient and her partner who was at the bedside. The
patient reported feeling increasing malaise and lower extremity edema for 1 month with
associated shortness of breath and chest pain (CP). She described the CP as a substernal
pressure and like someone was “sitting on her chest.” She also complained of orthopnea
and heartburn when lying flat, a dry cough that was now productive of white sputum, and
sinus congestion. She denied any nausea, vomiting, diarrhea, constipation or abdominal
pain, but did have 1 episode of posttussive emesis. She had previously been worked up for
anemia without any diagnosis being made. She denied any history of epistaxis,
menorrhagia, or melena. Blood sugars had been uncontrolled recently and were running
200-500 on her glucometer due losing her insurance and no longer having a primary care
physician.
Past Medical History: Type 2 Diabetes, Hypertension, Hyperlipidemia.
Family History: Sickle Cell Trait
Medications: Atorvastatin, Hydrochlorothiazide, Insulin Levemir and Novolog, and
Gabapentin.
Vital Signs: BP 184/91, HR 120, RR 20, T 37.1C, SpO2 96% RA, BMI 38.61
Physical Exam: On exam, the patient was an awake and alert obese female in mild
distress. She had crackles noted in the lower lung lobes bilaterally and a tachycardic
heartrate with a grade 2/6 systolic murmur. Jugular venous pulse was elevated. The
abdomen was soft, nontender, and nondistended. The lower extremities were tense and
edematous with nonpitting edema. Small purple lesions were scattered over the lower
extremities.
Labs:
• CBC: WBC 7.87, Hgb 7.1L, Hct 26.5L, Plts 422H
• CMP: Na+ 137, K+ 3.7, Cl- 108H, CO2 24, BUN 11,
Cr 1.05, Gluc 322H, Ca2+ 8.0L, TBili 0.2, AST 42H,
ALT 41, AlkPhos 186H, TProtein 5.6L, Albumin 1.9L,
Mg2+ 1.8.
• Troponin I: 0.132H
• Hemoglobin A1C: 13.9H
A. EKG from admission showing sinus
• D-Dimer: 1.27H
tachycardia (Rate 108) with nonspecific T wave
abnormalities.
• Respiratory Virus Panel: Negative

Discussion

Figures

B. Initial CXR showing no evidence of acute
cardiopulmonary disease.

D. ECHO report documenting a normal size left ventricle
with an ejection fraction of 51%. There is mild thickening
of the left wall. Segments of the basal inferoseptal and
mid inferoseptal walls are hypokinetic. Segments of the
basal inferior and mid inferior left ventricular wall are
akinetic. Findings were consistent with a pseudonormal
left ventricular filling pattern, with concomitant abnormal
relaxation and increased filling pressure (Grade 2
Diastolic Dysfunction).
There was normal ventricular size and function of the
right ventricle.

C. CTA of the chest showing no evidence of pulmonary
embolism or suspicious lymphadenopathy. Small
bilateral pleural effusions with associated atelectasis.

E. Cardiac MRI showing a
decreased ejection fraction
and focal areas of hypokinesis
involving the basal inferoseptum
and mid inferoseptal myocardium
with thickening of the wall. There
are areas suggestive of
fibrosis/scarring. No findings of sarcoidosis or infiltrative
cardiomyopathy.

Case Conclusion
During her admission, the patient underwent extensive evaluation for her complaint of
malaise. Her ECHO (Figure D) showed evidence of heart failure with abnormal ventricular
relaxation, which was consistent with the fibrosis/scarring noted on her cardiac MRI (Figure
E). The differential diagnoses were whether the cardiomyopathy was primarily related to her
DM or due to ischemia. Due to the elevated troponin, the patient eventually underwent a
coronary catheterization which showed partial occlusion of the right coronary artery. While
this finding was evidence of the presence of CAD, discussion amongst the care team felt
that the cardiomyopathy was primarily related to the patients long standing and markedly
uncontrolled DM, while this incident of acute decompensation was likely related to acute
ischemia.

Figure F: The effects of diabetes mellitus
systemically, on the myocardium, and on
individual cardiomyocytes3.

Functionally, one of the earliest manifestations of
DCM is left ventricular hypertrophy (LVH), primarily
affecting the ventricular septal and left posterior myocardial walls4, along with associated
diastolic dysfunction5. These early cardiac changes occur subclinically and are believed to
be present in 40-75% of patients with DM6. This is important because cardiac damage and
disease progression begin before patients ever develop clinical symptoms, which highlights
the challenge of how to effectively identify and treat patients with DCM.
Multiple studies have sought to use markers and tests such as B-type natriuretic peptide
(BNP), exercise stress testing, echocardiography, and nuclear imaging to identify patients
with subclinical disease, but none have proved to have sufficient sensitivity or specificity7,8.
As a result, an understanding and clinical awareness of diabetic cardiomyopathy by
providers when managing diabetic patients is imperative. The UK Prospective Diabetes
Study found that a 1% reduction in hemoglobin A1C (HbA1C) was associated with a 16% risk
reduction for the development of HF9. In patients with diagnosed HF though, DM
management had a more U-shaped effect, with the lowest mortality among patients with a
with a HbA1C of 7-8%2.
Another important decision in the management of patients with DM is medication selection.
Research has shown that SGLT-2 inhibitors are the most beneficial for DM patients both at
risk of developing HF or with established HF, while GLP-1 receptor agonists are beneficial in
establish HF1. Insulin, metformin, and sulfonylureas are acceptable alternatives and
thiazolidinediones and dipeptidyl peptidase-4 inhibitors (DPP-4) are not recommended in
patients at risk or with established HF1.
Understanding the development of DCM and how best to identify and treat this condition is
vital to improving patient morbidity and mortality.
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